Golodirsen (Vyondys 53) is used for the treatment of patients with DMD (Duchenne muscular dystrophy) in those who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Dosage: The recommended golodirsen dose is 30 mg/kg, which should be administered once weekly as 35 to 60 minute by intravenous infusion. In occurrence of a missed dose of golodirsen, it should be administered as soon as possible following the scheduled dose.
The most commonly reported vyondys side effects include:
- Abdominal pain
Warnings and Precautions:
- Patients receiving golodirsen 100 mg injection with known renal function impairment should be closely monitored while on therapy.
- Measure patients for glomerular filtration rate prior to the initiation of vyondys 100 mg injection therapy.
- Patients taking treatment with the drug named vyondys 53 are advised not to use this therapy concomitantly with other exon skipping therapies for DMD.
- The vyondys 53 uses could cause headache in patients. If you have a headache while taking this drug, talk with your healthcare team.